Bicifadine

Summary

Bicifadine (CHEMBL511099) is a phase-3 clinical-stage small molecule; indicated across 2 conditions including diabetic neuropathy.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• Indications: 2 conditions
• Clinical trials: 5
• Chemistry: 173.25 Da · C12H15N

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL511099
Name	Bicifadine
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	47953
Molecular formula	C12H15N
Molecular weight	173.25
InChIKey	OFYVIGTWSQPCLF-UHFFFAOYSA-N

SMILES: CC1=CC=C(C=C1)C23CC2CNC3

IUPAC name: 1-(4-methylphenyl)-3-azabicyclo[3.1.0]hexane

Also known as: Bicifadina, Bicifadine, BICIFADINE

Parent form; salt/anhydrous children: CHEMBL544862

Patent coverage: 429 distinct patent families (1,911 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 4 (assay-derived). Sample: Sodium-dependent noradrenaline transporter, Sodium-dependent serotonin transporter, Sodium-dependent dopamine transporter, Voltage-gated inwardly rectifying potassium channel KCNH2.

Bioactivity

ChEMBL activities: 3 potent at pChembl ≥ 5 of 4 total. Top 100 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
SLC6A2	7.26	IC50	55	nM	CHEMBL_ACT_18566347
SLC6A4	6.93	IC50	117	nM	CHEMBL_ACT_18566341
SLC6A3	6.04	IC50	910	nM	CHEMBL_ACT_18566365

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 disease in clinical trials (phase 1–3, investigational — not approved indications). Highest ChEMBL trial phase per disease; a non-cancer approved use is occasionally logged at phase 3 here.

Disease (in trials)	Phase	MONDO	EFO
diabetic neuropathy	2	MONDO:0006626	EFO:1000783

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 5.

Phase distribution

Phase	Trials
PHASE3	3
PHASE2	2

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00281645	PHASE3	COMPLETED	Long-Term Safety Study of Bicifadine for the Treatment of Chronic Low Back Pain
NCT00295711	PHASE3	COMPLETED	Efficacy and Safety of Bicifadine in the Treatment of Chronic Low Back Pain
NCT00295724	PHASE3	COMPLETED	Efficacy and Safety of Bicifadine in the Treatment of Chronic Low Back Pain
NCT00553592	PHASE2	UNKNOWN	Double Blind RCT of Bicifadine SR in Outpatients With Chronic Neuropathic Pain Associated With Diabetes
NCT00597649	PHASE2	TERMINATED	A 52-Week Study of Bicifadine in Patients With Chronic Neuropathic Pain Associated With Diabetic Peripheral Neuropathy

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).